Vertex Pharmaceuticals is an American Pharmaceutical company based in Boston, Massachusetts.
Vertex was founded in 1989 by Joshua Boger and Kevin J. Kinsella. Vertex was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
By 2004, its product pipeline focused on viral infections, inflammatory and autoimmune disorders, and cancer. It maintains headquarters in South Boston, Massachusetts, and two research facilities, in San Diego, California, and Oxford, England. The company's beginnings were profiled by Barry Werth in the 1994 book The Billion-Dollar Molecule and its further development in his 2014 book, The Antidote: Inside the World of New Pharma. In 2009, the company had about 1,800 employees, including 1,200 in the Boston area.
In January 2014, Vertex completed its move from Cambridge, Massachusetts to Boston, Massachusetts, and took residence in a new, $800 million complex. Located on the South Boston waterfront, it will mark the first time in the company's history that all of the roughly 1,200 Vertex employees in the Greater Boston area will be working together.
| Key people | Jeffrey Leiden, M.D., Ph.D., Chair, President and CEO Stuart A. Arbuckle, Executive Vice President and Chief Commercial Officer Kenneth L. Horton, Executive Vice President and Chief Legal Officer Lisa Kelly-Croswell, Senior Vice President, Human Resources David Altshuler, M.D., Ph.D., Executive Vice President, Global Research, and Chief Scientific Officer Megan Pace, Senior Vice President, Corporate Communications Amit K. Sachdev, Senior Vice President, Corporate Affairs and Public Policy Ian F. Smith, Executive Vice President and Chief Financial Officer |
|---|---|
| Traded as | NASDAQ: VRTX NASDAQ-100 Component S&P 500 Component |
| Industry | Pharmaceuticals & Biotherapeutics) |
| Headquarters | Boston, Massachusetts |
| Revenue | US$1.4 billion (2011) |
NPS is a customer loyalty metric that measures customers’ willingness to not only return for another purchase or service but also make a recommendation to their family, friends or colleagues.
It is a powerful and effective technique, which can greatly increase a company's revenue if used properly.
The main advantages of NPS are close correlation with a company's growth and easy collection, interpretation and communication of the data.
Yes, it is.
Net Promoter Score is a number from -100 from 100.
Scores higher than 0 are typically considered to be good and scores above 50 are considered to be excellent.
The industry average for Health Care / Major Pharmaceuticals is 0.
The final Net Promoter Score of a company strongly depends on a context in which the satisfaction is measured.
Consider an example: If Vertex Pharmaceuticals Incorporated sends out NPS surveys immediately after purchase, they are tracking their customers' initial excitement and the checkout experience.
On the other hand, if they survey their customers a few weeks after the purchase they are also tracking how satisfied their customers are with their products and services over time.
Therefore, comparing the NPS score of Vertex Pharmaceuticals Incorporated with your own without any further context is not that useful.
What is extremely useful though, is using the NPS methodology to track the satisfaction of your customers over time. That's where Customer.guru comes in.
How are your customers satisfied depending on:
We have estimated the Net Promoter Score of Vertex Pharmaceuticals Incorporated based on the publicly available information
including the sentiment of the company-related tweets, 3rd party reviews, and Alexa ratings.
Do you think this information is incorrect? Report incorrect information. Do you have more accurate data? Submit NPS score.